209 related articles for article (PubMed ID: 22117740)
1. [Recurrent and chronic central serous chorioretinopathy. Retina thickness evaluation one month after intravitreal bevacizumab injection].
Gregori-Gisbert I; Aguirre-Balsalobre F; García-Sánchez J; León-Salvatierra G; Mengual-Verdú E; Hueso-Abancéns JR
Arch Soc Esp Oftalmol; 2011 Dec; 86(12):407-11. PubMed ID: 22117740
[TBL] [Abstract][Full Text] [Related]
2. The treatment of recurrent central serous chorioretinopathy with intravitreal bevacizumab.
Lee ST; Adelman RA
J Ocul Pharmacol Ther; 2011 Dec; 27(6):611-4. PubMed ID: 21810026
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of intravitreal bevacizumab for acute central serous chorioretinopathy.
Aydin E
J Ocul Pharmacol Ther; 2013 Feb; 29(1):10-3. PubMed ID: 22925113
[TBL] [Abstract][Full Text] [Related]
4. Results of one-year follow-up examinations after intravitreal bevacizumab administration for chronic central serous chorioretinopathy.
Inoue M; Kadonosono K; Watanabe Y; Kobayashi S; Yamane S; Arakawa A
Ophthalmologica; 2011; 225(1):37-40. PubMed ID: 20693820
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab injection for central serous chorioretinopathy.
Lim SJ; Roh MI; Kwon OW
Retina; 2010 Jan; 30(1):100-6. PubMed ID: 20010322
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study.
Artunay O; Yuzbasioglu E; Rasier R; Sengul A; Bahcecioglu H
Curr Eye Res; 2010 Feb; 35(2):91-8. PubMed ID: 20136418
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab in central serous chorioretinopathy.
Jamil AZ; Rahman FU; Iqbal K; Ansari HM; Iqbal W; Mirza KA
J Coll Physicians Surg Pak; 2012 Jun; 22(6):363-6. PubMed ID: 22630094
[TBL] [Abstract][Full Text] [Related]
8. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
9. Morphologic changes and visual outcomes in resolved central serous chorioretinopathy treated with ranibizumab.
Ozdemir O; Erol MK
Cutan Ocul Toxicol; 2014 Jun; 33(2):122-6. PubMed ID: 23848591
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
11. Rapid and sustained resolution of serous retinal detachment in Sturge-Weber syndrome after single injection of intravitreal bevacizumab.
Shoeibi N; Ahmadieh H; Abrishami M; Poorzand H
Ocul Immunol Inflamm; 2011 Oct; 19(5):358-60. PubMed ID: 21823932
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab to treat acute central serous chorioretinopathy: short-term effect.
Seong HK; Bae JH; Kim ES; Han JR; Nam WH; Kim HK
Ophthalmologica; 2009; 223(5):343-7. PubMed ID: 19521133
[TBL] [Abstract][Full Text] [Related]
13. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
14. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab injection for central serous chorioretinopathy.
Nowroozzadeh MH
Retina; 2010 Sep; 30(8):1322-3; author reply 1323. PubMed ID: 20827148
[No Abstract] [Full Text] [Related]
16. Intravitreal bevacizumab injection for central serous chorioretinopathy.
Chhablani JK; Narayanan R
Retina; 2010 Sep; 30(8):1323-24; author reply 1324. PubMed ID: 20661171
[No Abstract] [Full Text] [Related]
17. Intravitreal bevacizumab for treatment of proliferative and nonproliferative type 2 idiopathic macular telangiectasia.
Roller AB; Folk JC; Patel NM; Boldt HC; Russell SR; Abramoff MD; Mahajan VB
Retina; 2011 Oct; 31(9):1848-55. PubMed ID: 21610563
[TBL] [Abstract][Full Text] [Related]
18. TWELVE-MONTH EFFICACY OF INTRAVITREAL BEVACIZUMAB INJECTION FOR CHRONIC, ATYPICAL, OR RECURRENT CENTRAL SEROUS CHORIORETINOPATHY.
Chung YR; Kim JW; Song JH; Park A; Kim MH
Retina; 2019 Jan; 39(1):134-142. PubMed ID: 29077604
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab versus the conventional protocol of photodynamic therapy for treatment of chronic central serous chorioretinopathy.
Lee JY; Chae JB; Yang SJ; Kim JG; Yoon YH
Acta Ophthalmol; 2011 May; 89(3):e293-4. PubMed ID: 20346078
[No Abstract] [Full Text] [Related]
20. Choroidal thickness and choroidal blood flow after intravitreal bevacizumab injection in eyes with central serous chorioretinopathy.
Okamoto M; Matsuura T; Ogata N
Ophthalmic Surg Lasers Imaging Retina; 2015 Jan; 46(1):25-32. PubMed ID: 25559505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
